Citadel Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Citadel Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-99,600	Closed	-$1.75M	–	15481
2021 Q3	$1.75M	Sell	99,600 -51,400	-34%	-$601K	﹤0.01%	6709
2021 Q2	$1.47M	Sell	151,000 -93,800	-38%	-$883K	﹤0.01%	7374
2021 Q1	$2.63M	Sell	244,800 -42,700	-15%	-$528K	﹤0.01%	5753
2020 Q4	$4.23M	Buy	287,500 +150,900	+110%	+$2.18M	﹤0.01%	3958
2020 Q3	$1.94M	Buy	136,600 +85,100	+165%	+$848K	﹤0.01%	4770
2020 Q2	$417K	Buy	51,500 +33,700	+189%	+$208K	﹤0.01%	7387
2020 Q1	$72K	Buy	+17,800	New	+$67.3K	﹤0.01%	8842

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Citadel Advisors's TRIL Position: Q4 2021 in Review

Citadel Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 798,500 shares — an estimated $14M sold.

Citadel Advisors first reported a position in TRIL in Q4 2017 and held it in 10 quarters. The position peaked at $60.4M in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Citadel Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Citadel Advisors sold 798,500 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $14M.
Citadel Advisors first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 10 quarters.
Citadel Advisors's Trillium Therapeutics Inc. position peaked at $60.4M in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.